Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932878 · ClinicalTrials.gov registry record · Phase 2
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
A Phase 2 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02932878 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 16 participants.
The verdict
NCT02932878, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
Interventions
- DRUG DSXS topical
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-09-02 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02932878
The ClinicalTrials.gov registry entry for NCT02932878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DSXS topical is the first listed.
NCT02932878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02932878 about?
NCT02932878 is a clinical study titled "An Open Label, Safety Study to Assess the Potential for Adrenal Suppression". An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
What is the current status of trial NCT02932878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-09-02. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT02932878?
The interventions under investigation include: DSXS topical (DRUG).
Who is sponsoring clinical trial NCT02932878?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.